Skip to main content

Table 2 Studies reporting the effects of the CONUT score on outcomes in patients with gastric cancer

From: Prognostic significance of the controlling nutritional status (CONUT) score in patients undergoing gastrectomy for gastric cancer: a systematic review and meta-analysis

Study Overall complication Mortality Reccurence/relapse-free survival Cancer-specific survival Overall survival
Kuroda [7] 37.1 vs 27.7% (P = 0.133) n.a. 5-year: 77.8 vs 90.6% (P = 0.017)
HR 2.63 (1.16–5.98), P = 0.021**
5-year: 82.3 vs 94.0% (P = 0.019)
HR 4.13 (1.62–10.55), P = 0.003**
5-year: 43.8 vs 84.8% (P < 0.001)
HR 2.72 (1.74–4.25), P < 0.001*
Zheng [8] n.a. n.a. 5-year: 51.6 vs 70% (Light vs normal) (P < 0.001)
HR 1.376 (1.005–1.884)*
55.2 vs 70% (Moderate vs normal) (P = 0.017)
HR 1.154 (0.726–1.836), P = 0.137*
n.a. 5-year: 53.2 vs 71.4% (Light vs normal) (P < 0.001)
HR 1.360 (0.984–1.879)*
54.5 vs 71.4% (Moderate vs normal) (P = 0.006)
HR 1.266 (0.753–2.126), P = 0.173*
Liu [9] 26.7 vs 21.9% (P = 0.161) n.a. n.a. 5-year: 39.3 vs 55.5% (P < 0.001)
HR 1.553 (1.080–2.232), P = 0.017*
n.a.
Ryo [13] 31.5 vs 26.4% 90-day: 1.4 vs 0.3% HR 1.33 (0.98–1.81), P = 0.0637** n.a. HR 1.74 (1.26–2.41), P = 0.0007*
Suzuki [14] 55.5 vs 36% (P = 0.09)
Infectious: 44.4 vs 25.7% (P = 0.08)
OR 2.36 (0.99–5.40), P = 0.046*
3 vs 0% (P = 0.09) n.a. 5-year: 64, 75 vs 33% (stage II/III; normal, light vs moderate and severe) (P = 0.003)
HR 3.75 (1.30–10.43), P = 0.015*
5-year: 88, 76 vs 51% (stage I; normal, light vs moderate and severe) (P = 0.044)
64, 53 vs 24% (stage II/III; normal, light vs moderate and severe) (P = 0.007)
HR 2.12 (1.18–3.69), P = 0.012*
  1. Data are shown for high CONUT group versus low CONUT group unless otherwise indicated. OR and HR is shown with 95% confidence interval. *Multivariable analysis. **Univariate analysis
  2. CONUT Controlling nutritional status, HR Hazard ratio, OR Odds ratio, n.a., not available